LV-FAH Gene Therapy - Castle Creek Biosciences, Inc. : Castle Creek Biosciences, Inc.

About
Technology
Pipeline
- D-Fi Gene Therapy for Dystrophic Epidermolysis Bullosa (DEB)
Patients & Families
- Epidermolysis Bullosa (EB)

Contact Us

Press Releases

LV-FAH Gene Therapy

Jan 5, 2022

LV-FAH Gene Therapy

Recent Posts

Castle Creek Biosciences Announces Publication of Preclinical Study for Potential In Vivo Gene Therapy in Nature Communications
Castle Creek Biosciences Raises $112.8 Million to Advance Novel Gene Therapies and Expand Pipeline
American Society of Gene & Cell Therapy (ASGCT) Annual Meeting Hybrid Conference
Society of Investigative Dermatology (SID) Annual Meeting

Castle Creek Biosciences, Inc.
405 Eagleview Boulevard
Exton, PA 19341

Connect with us:

©2024 Castle Creek Biosciences, Inc. All Rights Reserved. The registered dual crescent logo and “Castle Creek Biosciences” are trademarks of Castle Creek Biosciences, LLC.

Privacy Policy | Terms of Use